Tag: Pharmaceutical Industry
Browse by:
- ServicesStrategic Partnerships & Global EngagementClimate & BiodiversityFinancial CommunicationsChange & TransformationPublic Affairs & Government RelationsInternal Culture & EngagementIntegrated MediaAdvocacy CampaignsSocial Impact & ESGResearch, Analytics and MeasurementExecutive PositioningReputation & Brand ManagementCreative Strategy & DesignCorporate CommunicationCrisis, Issues & LitigationGeo-Commerce & Risk
- Sectors
- Regions
Health Corporate and Public Affairs Expert Yuko Kidoguchi Joins APCO as Director in Tokyo
Yuko Kidoguchi, award-winning health industry veteran with more than 25 years of experience in the pharmaceutical industry, joined APCO as a director in the firm’s Tokyo office, Seiko Indo, managing director of APCO’s Tokyo office, announced today. ...
Beyond Reshoring: A Call for Bold, Collaborative Policy to Secure the U.S. Pharmaceutical Supply Chain and Prevent Drug Shortages
Exploring the challenges of the U.S. pharmaceutical supply chain, this piece highlights the necessity for collaboration between pharmaceutical companies and government. It calls for a coordinated approach to address drug shortages and improve access to essential medications....
Corporate Affairs in the Pharmaceutical Industry: How to Succeed in a Complex and Evolving Landscape
This white paper explores the evolving challenges faced by corporate affairs leaders in the pharmaceutical industry, highlighting key factors like AI, supply chain vulnerabilities, regulatory changes and the growing importance of ESG and DEI considerations....
A Healthier MENA: The Balancing Act in Growing the Pharmaceutical Industry
The Middle East & North Africa (MENA) region is facing increasing health care demand due to longer life expectancy, lifestyle changes, and a rise in non-communicable diseases. Governments are implementing ambitious health care reforms with implications for the pharmaceutical industry....
ESG Pulse of Pharmaceutical Companies in Highly Regulated Markets
How are pharmaceutical companies performing on ESG priorities without “green hushing?”...